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Thiele, Todd E., Gertjan Van Dijk, L. Arthur 
Campfield, Francoise J. Smith, Paul Burn, Stephen C. 
Woods, Ilene L. Bernstein, and Randy J. Seeley. Central 
infusion of GLP-1, but not leptin, produces conditioned taste 
aversions in rats. Am. J. PhysioZ. 272 (Regulatory Integrative 
Comp. Physiol. 41): R726-R730, 1997.-Leptin (ob protein) 
and glucagon-like peptide-1-( 7-36) amide (GLP-1) are pep- 
tides recently proposed to be involved in the regulation of food 
intake. Although the ability of exogenous leptin and GLP-1 to 
modulate consummatory behavior is consistent with the 
suggestion that these peptides are endogenous regulatory 
agents, central administration of these peptides may have 
aversive side effects, which could explain the anorexia. In the 
present experiment, exposure to a saccharine taste was 
immediately followed by central administration of leptin or 
GLP-1 to determine if these drugs could produce a condi- 
tioned taste aversion (CTA) in rats. At doses equated for 
producing comparable reductions in short-term food intake, 
GLP-1, but not leptin, generated a robust CTA. Although 
leptin caused no aversion, this peptide was the only drug to 
cause relatively long-term reductions in food consumption (16 
h) and body weight (24 h). Hence, the results indicate that 
central GLP-1 produces aversive side effects, and it is argued 
that these nonspecific effects may explain the anorectic 
actions of GLP-1. 
food intake; body weight; satiety; peptides; lithium chloride 
EVIDENCE SUGGESTS THAT FOOD intake and body weight 
regulation are mediated, in part, by neuropeptides 
acting at the level of the central nervous system (CNS). 
Leptin, secreted from white adipose tissue (9, 20), and 
glucagon-like peptide-l-(7-36) amide (GLP-1), se- 
creted from the distal portion of the gut (8) and by 
neurons within the CNS (6, 7>, are peptides that have 
each recently been suggested to function as metabolic 
regulatory factors. Central infusion of exogenous GLP-1 
reduces food intake in rats (16, lS), and central admin- 
istration of exogenous leptin reduces food intake and 
body weight in mice and rats (1, 11,lS). 
Before a peptide that causes anorexia can be consid- 
ered a naturally occurring satiety factor, it must be 
determined that it does not induce other states that 
could account for reduced food intake (2, 19). Although 
the ability of exogenous leptin and GLP-1 to modulate 
consummatory behavior and/or adiposity is consistent 
with the suggestion that these peptides are endogenous 
regulatory agents, central administration of these pep- 
tides may have aversive side effects. Such nonspecific 
effects would likely cause reductions in eating and 
could explain the anorectic actions associated with 
central leptin and GLP-1 administration. 
To determine if infusion of leptin or GLP-1 into the 
third ventricle (i3vt) at doses that reduce short-term 
food intake is associated with aversive reactions, the 
present experiment examined the ability of these drugs 
to support the development of a conditioned taste 
aversion (CTA). When consumption of a novel taste is 
followed by intraperitoneal injection of the toxin lithium 
chloride (LiCl), rats avoid subsequent consumption of 
the taste, indicating that they have learned a CTA (14, 
15). In the present study, rats were given intraoral 
infusion of a saccharine taste and were then immedi- 
ately given a i3vt infusion of leptin or GLP-1. These 
peptides were administered at doses found to produce 
similar reductions in food intake over a 4-h period after 
infusion (see Table 1; data previously published in Ref. 
18). As a positive control to show that this general 
procedure could promote CTA learning, a third group of 
rats were given intraperitoneal injection of LiCl after 
saccharin exposure. The development of a CTA would 
suggest that administration of the drug that produced 
the CTA also produces aversive side effects. 
MATERIALS AND METHODS 
Animal preparation. Subjects were male Long-Evans rats 
weighing between 300 and 400 g at the onset of the experi- 
ment. They were individually housed in stainless steel cages 
and maintained on a 12:12-h light-dark cycle. Laboratory rat 
chow and water were provided ad libitum (except where 
noted). Under Equithesin (3.3 ml/kg ip) anesthesia, rats to be 
infused with leptin or GLP-1 or their vehicle were implanted 
with 21-gauge stainless steel cannulas (Plastics One, Roa- 
noke, VA) aimed at the third ventricle. With bregma and 
lambda at the same vertical coordinate, the sagittal venous 
sinus was carefully displaced laterally with a metal probe, 
and the cannulas were placed directly on the midline, 2.2 mm 
posterior to bregma and 7.4 mm ventral to dura, and fixed to 
the skull with anchor screws and dental acrylic. The cannulas 
were fitted with removable obturators that extended 0.5 mm 
beyond the tip of the guide cannula. All rats were implanted 
unilaterally with intraoral cannulas constructed of PE-100 
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Table 1. Four-hour food intake in rats after central 
infusion of drug 
Drug (n = 6 each) Food Intake, g 
Leptin (3.5 pg) 2.67 2 0.68* 
GLP-1 (10.0 pg> 2.23 k 0.48* 
sCSF 5.82 2 0.55 
Values are means 2 SE. ‘i’P < 0.05 for 3rd ventricular (i3vt) drug 
[leptin and glucagon-like peptide-l-(7-36) (GLP-l)] vs. i3vt syn- 
thetic cerebrospinal fluid (sCSF). These data were previously re- 
ported in Ref. 18. 
tubing. The cannulas were placed anterolateral to the first 
maxillary molar and threaded subcutaneously to exit the top 
of the head. Each rat was given 0.15 ml each of Chloromycetin 
(100 mg/ml SC) and gentamicin (40 mg/ml ip) prophylactically. 
When rats regained their preoperative body weights after 
surgery (2-3 wk), placement of i3vt cannulas were confirmed 
by administration of 10 ng angiotensin II in saline while the 
animals were water replete. Animals that did not drink at 
least 5 ml of water within 60 min were not used in the study. 
Taste aversion training. Rats were initially habituated to a 
Plexiglas observation chamber and intraoral fluid infusion by 
being placed in the chamber for 20 min./day over 4 days. On 
the last 2 days of habituation, rats received an intraoral 
infusion of 5 ml distilled water (0.5 ml/min) during the first 10 
min in the chamber. The rats were then assigned to one of 
three drug treatment conditions (leptin, GLP-1, or LiCl), and 
each treatment condition was further divided into two sub- 
groups (all subgroups were equated for body weight). On each 
of 2 conditioning days (separated by 1 day), rats were placed 
in the observation chamber for 5 min and intraorally infused 
with 2.5 ml of 0.15% saccharin delivered by infusion pump at 
a rate of 0.5 ml/min. This amount of saccharin is readily 
ingested by rats (15). During the infusion, rats were video- 
taped, and the amount of time (s) that passed before the rat 
rejected fluid (passive dripping or active fluid expulsion) was 
scored. Immediately after taste exposure, one of the sub- 
groups within each treatment condition was given i3vt infu- 
sion (3.5 pl manually infused with a Hamilton syringe over 60 
s; see Ref. 18 for details) of either leptin [Paired-Leptin; 3.5 ug 
dissolved in synthetic-cerebra-spinal fluid (sCSF; see Ref. 17 
for composition of sCSF; n = 5)] or GLP-1 (Paired-GLP-1; 10.0 
ug dissolved in sCSF; n = 5) or an intraperitoneal injection of 
LiCl (Paired-LiCl; 127 mg/kg; 0.15 M solution dissolved in 
sterile water; n = 4). Thus experience with the taste and the 
drug occurred at approximately the same time. Rats from the 
other subgroup of each treatment condition were given con- 
trol solutions (i3vt sCSF or intraperitoneal isotonic saline) 
immediately after taste exposure (Unpaired-Leptin, n = 5; 
Unpaired-GLP-1, n = 5; and Unpaired-LiCl, n = 5). 
After each conditioning day, unpaired rats were given i3vt 
infusion of leptin or GLP-1 or given intraperitoneal injection 
of LiCl (same doses described above). Paired rats were 
infused with sCSF or injected with saline. Animals were 
treated with the drug or the control solution, without expo- 
sure to the taste, and immediately returned to their home 
cages. With this experimental design, paired and unpaired 
subgroups of each treatment condition had similar exposure 
to drugs and to saccharin; however, in the paired subgroups, 
the drug was presented immediately after saccharin expo- 
sure, whereas unpaired subgroups received the taste and the 
drug on separate days. 
Assessment of conditioned taste aversions. Two indepen- 
dent measures were used to examine CTAs. First, on the 
second conditioning day (before drugs were administered) 
rejection of saccharin was used as an index of CTA. Immedi- 
ately after the second drug administration, two animals 
developed infections and were killed. Three days after the 
second conditioning trial, a second measure of CTA learning 
was assessed by measuring 24-h consumption of rats from 
two available bottles, one containing 0.15% saccharin and one 
containing distilled water. The saccharine preference ratio 
was calculated as the amount of saccharin consumed divided 
by total consumption of both fluids. 
Assessment of food consumption and body weight. On each 
day, the weight of rats and food hoppers was taken at -1000. 
In addition, hoppers were weighed at 1800 (to assess over- 
night 16-h food intake). Sixteen-hour food intake and 24-h 
body weight change of rats were assessed after the first 
administration of drug (leptin, GLP-1, or LiCl) and after the 
first administration of control solution (sCSF or isotonic 
saline). It should be noted that subjects received the i3vt or 
intraperitoneal injection of solutions (drug treatments pre- 
sented in a counterbalanced order) at various times of the day 
during the taste aversion procedure. Thus the 16-h consump- 
tion data and the 24-h body weight data represent the effects 
of the drugs during the measured periods but do not repre- 
sent the time interval immediately after drug exposure. 
Data analyses. Data from each CTA measure (fluid rejec- 
tion and two-bottle preference ratio) were analyzed with 
two-way, 2 X 3 (subgroup X drug) analyses of variance 
(ANOVA). The subgroup factor examined differences between 
paired and unpaired subgroups, whereas the drug factor 
examined differences between groups exposed to leptin, GLP- 1, 
or LiCl. Data from consumption and body weight measures 
were analyzed with mixed-factor, 2 x 3 (exposure X drug) 
ANOVA. The within-subjects exposure factor examined differ- 
ences after subject exposure to drug versus control solution, 
whereas the between-subjects drug factor examined differ- 
ences between groups exposed to either of the three drugs. 
When significant differences were found, post hoc analyses 
were conducted using t-tests. In all cases, P < 0.05 (2-tailed) 
indicated statistical significance. 
RESULTS 
Conditioned taste auersions. On the first conditioning 
day, saccharin was ingested throughout all or most of 
the 5-min infusion period, and there were no differ- 
ences among groups. Fluid rejection data collected after 
CTA training are presented in Fig. lA, and saccharin 
preference data collected during the two-bottle test are 
presented in Fig. 1B. Relative to unpaired subgroups, 
rats that received saccharin paired with either GLP-1 
or LiCl rejected saccharin earlier in the test session. 
Furthermore, rats had a decreased preference for sac- 
charin if that taste had been paired with i3vt GLP-1 or 
intraperitoneal injection of LiCl. With both measures, 
pairing with leptin did not alter the acceptability of the 
saccharine taste. These results are confirmed by the 
following analyses. 
An ANOVA performed on the fluid rejection data 
revealed a significant subgroup effect [F( 1,23) = 25.151 
and a significant interaction effect between the sub- 
group and drug factors [F(2,23) = 6.531. Post hoc tests 
revealed that, although subgroups Paired-GLP- 1 and 
Paired-LiCl differed from their control subgroups (Un- 
paired-GLP-1 and Unpaired-LiCl, respectively), sub- 
groups Paired-Leptin and Unpaired-Leptin did not 



















Fig. 1. Mean (+SE) latency to reject intraorally infused saccharin 
(A) and preference for saccharin in a consumption test (B) after 
conditioned taste aversion training. Preference was defined as con- 
sumption of saccharin divided by total fluid (saccharin plus water) 
consumption. Filled bars represent paired subjects that received 
saccharin immediately followed by drug [leptin (3.5 ug), glucagon- 
like peptide-l-(7-36) (GLP-1) (10.0 ug), or LiCl (127 mg/kg)], and 
open bars represent unpaired subjects that received saccharin and 
drug on separate days. + Significant at P < 0.05 relative to unpaired; 
*P < 0.001 relative to unpaired. 
rin preference data revealed a significant subgroup 
effect [F(l,Zl) = 29.091, a significant drug effect 
[F(2,21) = 9.111, and a significant interaction effect 
[F(2,21) = 6.131. Post hoc tests showed that paired 
subgroups treated with GLP-1 and LiCl demonstrated 
significant reductions in saccharin preference ratio 
relative to controls; again, subgroups Paired-Leptin 
and Unpaired-Leptin did not differ significantly. 
Drug effects on food consumption and body weight. 
Overnight 16-h food consumption after the first drug or 
control treatment is presented in Fig. 2A, and data 
representing 24-h change in body weight are presented 
in Fig. 2B. Only i3vt leptin reduced overnight 16-h food 
consumption relative to the control solution (sCSF); 
consumption after i3vt GLP-1 infusion or LiCl injection 
was not reduced when compared with that after the 
control drug (sCSF and saline, respectively). The same 
trend is visible with the body weight data; only leptin 
caused reduction of body weight during the 24-h mea- 
surement. 
ANOVA performed on the consumption data revealed 
a significant exposure effect [F(l,26) = 17.261 and a 
significant interaction between the exposure and drug 
effects [F(2,26) = 3.521. Tests revealed that the only 
drug to cause a significant difference relative to the 
control infusion was leptin; neither GLP-1 nor LiCl 
differed from its respective controls. Likewise, ANOVA 
run on the body weight data revealed significant drug 
[F(2,26) = 7.191, exposure [F( 1,26) = 7.121, and interac- 
tion [F(2,26) = 4.211 effects. Again, tests revealed that 
only leptin-treated animals differed from the control 
treatment. 
DISCUSSION 
At doses that produce similar reductions of short- 
term food intake (see Table 1; Ref lS>, i3vt infusion of 
GLP-1, but not leptin, generated a robust CTA. Further- 
more, these results were obtained using two indepen- 
dent measures of CTA learning (latency to reject intra- 
oral saccharin and a two-bottle, saccharin versus water 
preference test). Because the development of a CTA 
implies that the drug supporting the aversion produces 
aversive, nonspecific effects, an alternative explanation 
for the previously observed short-term anorectic ac- 
tions of GLP-1 is that aversive effects of the drug reduce 
food intake. It may be argued that, whereas GLP-1 
produced relatively immediate aversive effects, a delay 
in the onset of aversive side effects produced by leptin 
infusion may have prevented CTA learning. However, 
because strong taste aversions can be obtained even 
when the toxin is presented 6-h after the taste (13), any 
aversive effects produced by leptin would presumably 
occur more than 6 h after drug infusion. These effects 
could not explain the reductions in food intake found 
within the first few hours after leptin infusion (e.g., Ref. 
18). Thus, although the doses of both leptin and GLP-1 
administered in the present study produce similar 








Leptin GLP-1 LiCl 
Fig. 2. Mean (+SE) 16-h food consumption (A) and 24-h change in 
body weight (B) in rats on first day of exposure to drug (filled bars) 
and to control solution (synthetic cerebrospinal fluid or saline; open 
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via a mechanism apparently unrelated to effects that 
support CTAs. Additionally, although it may be argued 
that a larger dose of centrally infused leptin may 
produce a CTA, the present results demonstrate that a 
dose exists that produces robust reductions in food 
intake and body weight without inducing aversive side 
effects. Finally, because peripheral injection of leptin 
causes reductions in food intake and adiposity (1), the 
possibility remains that peripheral administration of 
leptin may be associated with aversive side effects. 
Although the present results argue that caution is 
necessary when interpreting the anorectic actions of 
GLP-1, the data do not necessarily exclude the possibil- 
ity that GLP-1 is an endogenous satiety factor. Exen- 
din, a GLP-1 receptor antagonist, produces small but 
significant increases in food intake in satiated rats, 
supporting the possibility that GLP-1 is an endogenous 
satiety agent (16). A similar pattern of results has been 
observed with the proposed anorectic agent cholecysto- 
kinin octapeptide (CCK-8); CCK-&receptor antago- 
nists increase food consumption in satiated rats (5,lZ). 
Furthermore, like GLP-1, high doses of CCK-8 reduce 
food intake and produce a CTA (3). On the other hand, 
at lower doses, CCK-8 produces anorexia without sup- 
porting a CTA. Finally, both CCK-8 and GLP-1 activate 
c-Fos expression in similar brain stem areas (4, 10,lS). 
Given the similarities between CCK-8 and GLP-1, it 
seems possible that lower doses of central GLP-1 (i.e., 
~10.0 ug) could reduce acute eating in the absence of 
aversive side effects. It is also possible that the aversive 
side effects associated with GLP-1 are due to i3vt 
administration, but that injection of the drug into 
specific sites (e.g., hypothalamic nuclei) could reduce 
food intake in the absence of aversion. 
The anorectic actions of GLP-1 have typically been 
examined over the first several hours after drug admin- 
istration (16), and we have previously found compa- 
rable results using the same dose of GLP-1 as used in 
the present experiment (see Table 1; Ref. 18). In the 
present experiment, however, the effects of GLP-1 on 
food intake over a relatively long postinfusion interval 
(i.e., 16 h or longer) were insignificant. Thus GLP-l- 
induced anorexia appears to be relatively short lived. 
The effects of leptin on consummatory behavior are, 
therefore, different from those of GLP-1, as leptin 
reduced food intake and body weight over the longer 
interval in the present experiment. 
Using c-Fos immunoreactivity as an indication of 
neural activity, i3vt infusion of either leptin or GLP-1 
has been found to induce neuronal activity in hypotha- 
lamic and limbic forebrain regions involved in the 
regulation of feeding behavior (16, 18). In addition, 
GLP-1, but not leptin, was found to stimulate neuronal 
activity in several brain stem areas, including the 
nucleus of the solitary tract, lateral parabrachial 
nucleus, and area postrema (18), regions also activated 
by the toxin LiCl (14, 15). Thus, although it is possible 
that both leptin and GLP-1 have satiating properties, 
central GLP-1 infusion also produces aversive side 
effects that may be caused by this peptide’s stimulation 
of brain stem regions. Together, c-Fos immunoreactiv- 
ity data (18) and the present CTA and consumption 
data suggest that leptin and GLP-1 produce their 
anorectic actions via different mechanisms. 
Perspectives 
Over the last several years, our ability to identify 
putative anorectic compounds that are involved in the 
regulation of food intake and body weight has increased 
dramatically. However, reduced food intake is not suffi- 
cient evidence that a compound is an endogenous 
regulatory agent; it may produce anorexia by inducing 
a variety of side effects, including aversive states (e.g., 
visceral illness or malaise, fear, pain), motor impair- 
ment, sleepiness, or behavioral disorganization (2, 19). 
As reported here, CTA procedures can provide impor- 
tant screens for the ability of a compound to induce 
aversive states. We suggest that multiple measures of 
the effects of an agent (including but not limited to its 
effect on food intake and its ability to support a CTA) 
need to be employed before ascribing a role for that 
agent as an endogenous regulator of food intake and 
body weight. 
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